(NASDAQ: UBX) Unity Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Unity Biotechnology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast UBX's revenue for 2026 to be $341,661,614, with the lowest UBX revenue forecast at $341,661,614, and the highest UBX revenue forecast at $341,661,614. On average, 1 Wall Street analysts forecast UBX's revenue for 2027 to be $718,436,059, with the lowest UBX revenue forecast at $718,436,059, and the highest UBX revenue forecast at $718,436,059.
In 2028, UBX is forecast to generate $1,086,260,175 in revenue, with the lowest revenue forecast at $1,086,260,175 and the highest revenue forecast at $1,086,260,175.